Patent: 9,856,320
✉ Email this page to a colleague
Summary for Patent: 9,856,320
| Title: | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| Abstract: | The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. |
| Inventor(s): | Cogswell; John P. (Yardley, PA), Goldberg; Stacie M. (Potomac, MD), Gupta; Ashok Kumar (Clarksburg, MD), Jure-Kunkel; Maria (Plainsboro, NJ), Wang; Xi-Tao (Wellesley, MA), Wigginton; Jon M. (Rockville, MD) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 14/400,667 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,856,320 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,856,320
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | ACTEMRA | tocilizumab | Injection | 125276 | January 08, 2010 | ⤷ Start Trial | 2033-05-13 |
| Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | March 25, 2011 | ⤷ Start Trial | 2033-05-13 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | December 22, 2014 | ⤷ Start Trial | 2033-05-13 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | October 04, 2017 | ⤷ Start Trial | 2033-05-13 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | August 27, 2021 | ⤷ Start Trial | 2033-05-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,856,320
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013173223 | ⤷ Start Trial |
| United States of America | 9212224 | ⤷ Start Trial |
| United States of America | 2025270322 | ⤷ Start Trial |
| United States of America | 2025263486 | ⤷ Start Trial |
| United States of America | 2025257136 | ⤷ Start Trial |
| United States of America | 2024417471 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
